Showing results (141-150 of 196) with videos related to
Sort By:
Pageof 20
Leukemia & Lymphoma|April 25, 2019
Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practicePaul J Hampel, Wei Ding, Timothy G Call, et al.Blood|August 15, 2022
Progression and survival of MBL: a screening study of 10 139 individualsSusan L Slager, Sameer A Parikh, Sara J Achenbach, et al.Blood|August 10, 2007
A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemiaGabrielle S Sellick, Lynn R Goldin, Ruth W Wild, et al.Journal of the National Cancer Institute. Monographs|September 1, 2014
Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes ProjectSusan L Slager, Yolanda Benavente, Aaron Blair, et al.Leukemia & Lymphoma|May 26, 2020
Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practiceAmber B Koehler, Nelson Leung, Timothy G Call, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemiaTait D Shanafelt, Thomas E Witzig, Stephanie R Fink, et al.British Journal of Haematology|September 16, 2009
Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progressionWei Ding, Grzegorz S Nowakowski, Traci R Knox, et al.Blood Cancer Journal|May 11, 2021
Distinct immune signatures in chronic lymphocytic leukemia and Richter syndromeYucai Wang, Sutapa Sinha, Linda E Wellik, et al.American Journal of Hematology|April 12, 2014
Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cellsClive S Zent, Ronald P Taylor, Margaret A Lindorfer, et al.Mayo Clinic Proceedings|August 6, 2019
Etiologies of Extreme Thrombocytosis: A Contemporary SeriesRonan W Hsieh, Aishwarya Ravindran, Christopher C Hook, et al.Pageof 20